Eiger BioPharmaceuticals (STU:72C) Marketable Securities: €0.00 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Marketable Securities?

Eiger BioPharmaceuticals STU:72C 10 Marketable Securities is €0.00 Mil as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Eiger BioPharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2023 was €0.00 Mil.

Eiger BioPharmaceuticals's annual Marketable Securities increased from Dec. 2021 (€58.94 Mil) to Dec. 2022 (€69.05 Mil) but then declined from Dec. 2022 (€69.05 Mil) to Dec. 2023 (€0.00 Mil).

Eiger BioPharmaceuticals  (STU:72C) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Eiger BioPharmaceuticals Marketable Securities Related Terms

Eiger BioPharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Marketable Securities Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.06 82.18 58.94 69.05 0.00

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.54 69.05 28.27 0.00 0.00
STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €0.00 Mil mean?
Eiger BioPharmaceuticals (STU:72C) has a Marketable Securities of €0.00 Mil as of Dec. 2023. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Marketable Securities too high?
Eiger BioPharmaceuticals' current Marketable Securities is €0.00 Mil. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Marketable Securities compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Marketable Securities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Marketable Securities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Marketable Securities of €0.00 Mil. The current Marketable Securities is €0.00 Mil. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Marketable Securities is €0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price